OssDsign announced the milestone of 5,000 patients treated with nanosynthetic bone graft OssDsign Catalyst in the U.S. This is an increase from 2,000 patients treated by September 2023. The product was launched in the U.S. in 2021.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body. Twelve-month results from the clinical study TOP FUSION show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with OssDsign Catalyst.
“With 5,000 patients treated, the use of OssDsign Catalyst is not just growing, it’s accelerating. This is a significant leap from the earlier announcements of 2,000 patients treated in September 2023 and 1,000 patients in May 2023, demonstrating the rapid pace with which we are building our orthobiologics business,” said Morten Henneveld, CEO of OssDsign.
OssDsign announced the milestone of 5,000 patients treated with nanosynthetic bone graft OssDsign Catalyst in the U.S. This is an increase from 2,000 patients treated by September 2023. The product was launched in the U.S. in 2021.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in...
OssDsign announced the milestone of 5,000 patients treated with nanosynthetic bone graft OssDsign Catalyst in the U.S. This is an increase from 2,000 patients treated by September 2023. The product was launched in the U.S. in 2021.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body. Twelve-month results from the clinical study TOP FUSION show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with OssDsign Catalyst.
“With 5,000 patients treated, the use of OssDsign Catalyst is not just growing, it’s accelerating. This is a significant leap from the earlier announcements of 2,000 patients treated in September 2023 and 1,000 patients in May 2023, demonstrating the rapid pace with which we are building our orthobiologics business,” said Morten Henneveld, CEO of OssDsign.
Copy to clipboard 
